AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca shares open lower after rare disease drug fails to meet main trial goal
AstraZeneca PLC (LSE:AZN) shares opened lower on Wednesday after a late-stage trial of its experimental treatment for AL amyloidosis failed to meet its primary target in the overall patient group. The CARES phase III study tested anselamimab, a drug designed to clear harmful protein deposits in organs.
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AstraZeneca Meets All Key Goals in Phase III Hypertension Study
AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.
Here's Why Astrazeneca (AZN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AstraZeneca shares show signs of life after successful trials of hypertension drug
Baxdostat trials showed immense promise for huge available market.
AstraZeneca drug lowers high BP in late-stage study; shares rise
AstraZeneca 's experimental drug baxdrostat has been successful in lowering high blood pressure in a late-stage study of people whose condition was hard to control or treat, the Anglo-Swedish drugmaker said on Monday, sending shares up 2%.
AstraZeneca and GSK slide on Trump threats but analysts see positive catalysts ahead
Shares in AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) were both down over 1% on Friday, but the shares are worth buying, analysts at Shore Capital said. Blue-chip shares across London and Europe were lower on Friday, after Donald Trump scaled up his tariff rhetoric again.
Trumps 200% tariffs. Here's what it means for UK pharma investors
UBS has flagged a fresh risk for European drugmakers after President Trump said pharmaceuticals imported into the US could soon face tariffs of up to 200%. The comments, made earlier this week, revive concerns over protectionist policies targeting medicines not manufactured on American soil.
AstraZeneca: Market isn't pricing in the potential of late-stage pipeline, says bank
If you're looking for a solid growth story in the pharma sector, AstraZeneca PLC (LSE:AZN) should be on your radar. Berenberg's latest update paints a bright picture, highlighting some exciting pipeline readouts that haven't yet made their way into the share price.
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 billion in sales.
AstraZeneca: Just What The Doctor Ordered
AstraZeneca is a classic GARP stock with robust growth, an undervalued share price, and a strong drug pipeline supporting future earnings expansion. Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations, and key therapy areas like oncology and respiratory are driving double-digit growth. Shares are trading at a 16% discount to fair value, offering 21% upside potential over the next year, with a secure, market-beating 2.3% dividend yield.
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics is in advanced talks with AstraZeneca for a potential $15B licensing deal for ivonescimab, boosting its cash runway and strategic position. Ivonescimab shows strong PFS data versus Keytruda in NSCLC, but mixed OS results could delay U.S. approval and complicate regulatory pathways. Summit is doubling down on ivonescimab, expanding clinical collaborations and targeting a $90B addressable market beyond NSCLC.
